Amryt Pharma (Amryt Pharma) Common Stock : $25.6 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Common Stock?

Amryt Pharma's quarterly common stock increased from Mar. 2022 ($25.6 Mil) to Jun. 2022 ($25.6 Mil) but then declined from Jun. 2022 ($25.6 Mil) to Sep. 2022 ($25.6 Mil).

Amryt Pharma's annual common stock increased from Dec. 2019 ($11.9 Mil) to Dec. 2020 ($13.9 Mil) and increased from Dec. 2020 ($13.9 Mil) to Dec. 2021 ($25.5 Mil).

Amryt Pharma Common Stock Historical Data

The historical data trend for Amryt Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Common Stock Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Common Stock

Get a 7-Day Free Trial

25.40

25.20

11.92

13.85

25.50

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Common Stock	Get a 7-Day Free Trial															25.26	25.50	25.57	25.59	25.56

Amryt Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).